ArticleClinical and molecular hepatology2025
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
Hiroaki Kanzaki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.